Remote assessment for people with Parkinson's disease
Official title: PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
Run by University College, London · NCT06151002 · Data updated 2026-11-12
This study is testing whether an online questionnaire and saliva samples can help people with Parkinson's disease learn about their genetics and find out if they might qualify for future clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | University College, London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | February 15, 2020 |
| Main results expected | January 1, 2028 |
| Study ends | August 20, 2040 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06151002 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with a formal diagnosis of Parkinson's disease who do not carry a GBA variant.
✕Probably not a fit
Patients with a confirmed GBA variant or those with other neurological disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PD Frontline is an observational study aimed at preparing individuals with Parkinson's disease for participation in clinical trials. Participants complete an online questionnaire and receive a saliva collection kit to provide samples for genetic testing of the GBA1 and LRRK2 genes, which are associated with Parkinson's disease. The study seeks to identify potential candidates for gene-targeted trials and keep participants informed about relevant research opportunities based on their genetic results.
Why it matters
Potential benefit: If successful, this study could enhance the recruitment of patients for targeted therapies in Parkinson's disease.
How similar studies have gone: Other studies focusing on genetic testing in Parkinson's disease have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Formal diagnosis of Parkinson Disease Exclusion Criteria: * Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI. * History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration) * Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease. * Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Where it's running
-
University College London (UCL)
London, United Kingdom Recruiting
Study contacts
- Study coordinator: PD Frontline Team
- Email: pdfrontline@ucl.ac.uk
- Phone: 020 8016 8413
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.